Cell-derived microvesicles are membrane vesicles produced by the outward budding of the plasma membrane and released by almost all types of cells. These have been considered as another mechanism of intercellular communication, because they carry active molecules, such as proteins, lipids and nucleic acids. Furthermore, these are present in circulating fluids, such as blood and urine, and are closely correlated to the progression of pathophysiological conditions in many diseases. Recent studies have revealed that microvesicles have a dual effect of damage and protection of receptor cells. However, the nature of the active molecules involved in this effect remains unclear. The present study mainly emphasized the mechanism of microvesicles and the active molecules mediating the different biological effects of receptor cells by affecting autophagy, apoptosis and inflammation pathways. The effective ways of blocking microvesicles and its active molecules in mediating cell damage when microvesicles exert harmful effects were also discussed. K E Y W O R D S active molecules, apoptosis, autophagy, inflammation, lipids, microvesicles, miRNA, proteins | 7895 LV et aL. How to cite this article: Lv Y, Tan J, Miao Y, Zhang Q. The role of microvesicles and its active molecules in regulating cellular biology. J Cell Mol Med. 2019;23:7894-7904. https ://doi.
| INTRODUC TI ON
Microvesicles (MVs) are a kind of nanoscale membrane vesicles released during cell activation, apoptosis and mechanical injury, and these are collectively called extracellular vesicles with exosomes and apoptotic bodies. In as early as 1946, Chargaff et al 1 first discovered that plasma contains a subcellular 'factor' that can promote thrombosis, and subsequent studies have mostly used extracellular vesicles to describe this kind of substance. In recent years, the study of exosomes has become more and more mature, while unknown MVs have attracted more and more attention. It was found that MVs carry proteins, lipids, nucleic acids and other active components expressed in source cells, which can promote coagulation, participate in immunomodulation, induce angiogenesis and initiate apoptosis after interactions with target cells. 2 Furthermore, these play an important role in a variety of diseases (such as cardiovascular disease, 3 tumour, kidney disease and immune disease).
Previous studies have shown that MVs exert adverse biological effects when it interacts with target cells. For example, in cardiovascular disease, MVs can cause myocardial hypertrophy and mediate the progression of atherosclerosis and heart disease. 4 In ischaemic encephalopathy, MVs can promote the progression of ischaemic encephalopathy. 5 MVs can induce target cell injury by reducing cell viability, 6 promoting cell dysfunction and inflammation after interaction with cardiomyocytes, 7 endothelial cells and nerve cells. The investigators considered that the damage of MVs may be correlated to the bad state of the source cells. In recent years, it has been found that MVs from mesenchymal stem cells can prevent unilateral ureteral obstruction 8 and that endothelial progenitor cell (EPC)-derived MVs have played a protective role in renal ischaemia-reperfusion injury. 9 Furthermore, adipose tissue mesenchymal stem cell-derived MVs have effects of anti-inflammatory and cartilage protection. 10 The protective effect of MVs may be attributed to the fact that its parent cells are stem cells with regenerative and repairing effects.
As a carrier of transmission between cells, MVs carry specific active components of stem cells, and targets and transfers these protective substances, which causes the biological effects of cells to change to a beneficial direction. Therefore, it was considered that the different functions of MVs may be correlated to its active components.
In general, MVs in different cells in body fluids play a specific role. This role is mainly correlated to the various active components carried by MVs. The present study reviews the mechanism of the biological effects of MVs and its related active molecules in vivo, and the effective ways to alleviate the adverse effects of MVs. The aim of the present study was to explore the mechanism of MVs in regulating cellular biological effects and provide a theoretical basis for finding new therapeutic schemes for clinical diseases.
| MVS AND ITS AC TIVE MOLECULE S

| Characteristics of MVs under different conditions
Microvesicles are spherical membranous vesicles encapsulated by a lipid molecular layer, and the cell spontaneously or, under certain conditions, the cell membrane phosphate ester serine valgus, which is redistributed to the outer side of the membrane in the bud and is released to the cell outside the subcellular component. 11 shown that MVs can be derived from many types of cells, such as endothelial cells, erythrocytes, leucocytes, platelets and nerve cells, 12 and in response to different stimuli, the release level of MVs in diseases is significantly higher than normal levels, such as the elevated level of endothelial microvesicles (EMVs) in cardiovascular disease, 13 and hepatocyte from patients with hepatocellular carcinoma releases more MVs than normal hepatocytes. 14 An interesting study revealed that the co-culture of normal bone marrow mesenchymal cell-derived MVs with multiple myeloma cells can reduce the viability, proliferation and migration of multiple myeloma cells, while MVs from multiple myeloma patients can enhance these biological effects. 15 This shows that MVs produced in diseases are not only different in number from the normal state, but also have different biological effects. The main reason for these different effects is correlated to the changes in bioactive components carried by MVs.
Microvesicles come from many types of cells, carry active ingredients that have similarity with maternal cell components and contain some active analogous components and specific markers of the source cells. 16, 17 The data are summarized in Table 1 . Therefore, the same cellderived MVs should carry the same active components of parent cells.
However, an interesting phenomenon was found. It was detected that MVs derived from apoptosis mainly carried CD31/annexin V, while MVs produced when endothelial cells were activated mainly carried CD105 or CD62E. 18 In addition, the components of endothelial MV expression in different diseases are not the same. For patients with sleep disorders, EMVs mainly carried CD3, CD62E, CD42B, PECAM and E-selectin. 19, 20 In acute ischaemic stroke, EMVs mainly carried CD105, CD54, CD45, CD144, CD41A and CD4. 21 In viral myocarditis, EMVs mainly carry CD31, CD144, CD3 and CD62E. 22 This phenomenon reveals that in same cells in different environments or disease conditions, the derivative of MV-borne active molecules varies. Therefore, there is reason to consider that MVs carry different active molecules and play an important role in different biological effects in cells.
| Active molecules carried by MVs
Microvesicles comprise of a phospholipid bilayer derived from the parental cell plasma membrane, secretory proteins and genetic material transmitted in the cytoplasm. These specific molecules Mediates inflammation and subsequent vascular damage 17, 84, 87 Abbreviations: GPIbα, GPIIb/IIIa, platelet-specific autoantibody; MadCAM1, mucosal addressin cell adhesion molecule-1; PF4, platelet factor 4; RANTES, regulated upon the activation of normal T cell expressed and secreted; VCAM-1, vascular cell adhesion molecule-1.
TA B L E 1 Bioactive substances produced by MVs from different cell sources and their biological effects on target cells
derived from parental cells are packaged in a bilayer structure or carried on the membrane surface, which is called active ingredients.
In When the active molecules were inhibited, the effect of MVs on the biological effects of receptor cells was significantly reduced. determined to be involved in regulating distal immune response. 26, 27 In addition, the pro-coagulant cascade and mediating cartilage regeneration are also important physiological functions of active lipids. Phosphatidylserine and tissue factor (TF), which are expressed by MVs, are directly involved in the activation of the coagulation cascade in the body. 28 TF is inhibited in resting cells. Furthermore, sphingosine is hydrolysed after stress injury, thereby eliminating the inhibition of TF, which leads to TF activation, 29 
| B I OLOG I C AL EFFEC TS OF AC TIVE MOLECULE S
| Lipid active molecules and their biological effects
| Protein active molecules and their biological effects
| Nucleic acid active molecules and their biological effects
Nucleic acid is one of the most basic substances to maintain normal life. It is also one of the most important active components carried by MVs, which include microRNA, mRNA, RNA and DNA. As Microvesicles carry and transfer genetic material to target cells, which has been confirmed in many studies. Among these, micro-RNA-17-92 clusters carried by MVs were considered to affect the viability of target cells in a dose-dependent manner, after entering the target cells. 36 EMVs carrying microRNA-19b into perivascular adipose tissue were considered to promote the secretion of inflammatory cytokines and macrophage infiltration in adipose tissues. 37 Transferring microRNAs from platelet MVs to tumour cells and endothelial cells has been considered to induce apoptosis. 38, 39 Studies have revealed that MVs affect gene expression in target Furthermore, the activated PI3K-Akt signal acts on the downstream substrate endothelial nitric oxide synthase (eNOS). The eNOS is an important regulator of angiogenesis and vascular tension, which can trigger the process of angiogenesis, leading to cell proliferation, differentiation and angiogenesis. 46 MVs activate the PI3K-Akt autophagy signalling pathway, and play a protective role in target cells. 47 However, when the autophagy signal is overexpressed or autophagy is inhibited, 48, 49 MVs can induce apoptosis and damage cells. Different cell-derived MVs and its expressed active molecules activate the PI3K-Akt pathway in receptor cells and regulate target cells to produce different biological effects. At the same time, the TRAIL carried by MVs may participate in and cooperate with the apoptotic effect of FasL. 56 FasL not only induces apoptosis, but also promotes inflammation. 57 Hence, this may be in- ASC plays an important role in activating caspase-1, which is different from FAS/FASL-induced programmed cell death and considered to be the pathological death of cells under inflammatory and stress conditions. 59 protein into pro-inflammatory monomer C-reactive proteins after myocardial infarction, and promotes inflammation. 64 The study conducted by De Souza et al 65, 66 revealed that MVs can regulate the activation of NF-κB when it transported microRNAs (microRNA-27) expressed in parental cells into the target cell. Although its specific mechanism remains unclear, the role of MVs in it is self-evident.
| MVs and its active molecules regulate apoptosis through the Fas/FasL pathway
| MVs and its active molecules regulate inflammation through the NF-κB pathway
Various cytokines and pathways regulate inflammatory pathways in cells. These are closely correlated to signal transduction pathways, such as autophagy and apoptosis, and together maintain effective changes in cellular biological effects.
| EFFEC TIVE WAYS OF B LO CKING CELL DAMAG E MED IATED BY MVS AND ITS AC TIVE MOLECULE S
As an important mediator of intercellular signal transduction in 
| Blocking the interaction of MVs and its active molecules with receptor cells and transduction of the downstream signalling pathway
Microvesicles mediate the biological changes in target cells through a variety of ways. Hence, there are many methods to block the in- 
| Mediated MV clearance
In response to various stimuli (such as oxidative stress, inflammation, vascular shear stress), the level of circulating MVs increases, causing a series of pathophysiological changes in the body. In order to maintain the stability of the internal environment, the body can remove these MVs to a certain extent, thereby reducing the adverse effects of MVs on cells and organs. Microvesicles from different cell sources in circulation can bind to cells that mediate its clearance and remove through the liver, spleen and lungs. 71, 72 The clearance of MVs is associated with its surfactants and receptors expressed on the cell surface. Phosphatidylserine, which is carried on the surface of MVs, can bind to the developmental endothelial cell locus 1 (Del-1) expressed on endothelial cells. This promotes the endothelial cell uptake and clearance of circulating MVs. 73 
| Reduce harmful MV release
In order to maintain the stability of the internal environment, the MVs to target cells. 68 Aspirin also inhibits the activation of vascular parietal cells by reducing the release of MVs. 77 Resveratrol can reduce the levels of TNF-α and EMVs in peripheral blood by a cascade of intracellular NF-κB molecules and has a good effect on vascular endothelial function and systemic inflammation. 68 Acetylsalicylate treatment can reduce the number of circulating endothelial cells and PMVs in patients, and has been widely used in the treatment of cardiovascular diseases. 78 Studies have shown that the dietary intake of polyunsaturated fatty acids, fruits and vegetables can reduce leucocyte activation, platelet aggregation and MV shedding, thereby reducing the risk of cardiovascular disease and delaying the progression of atherosclerotic thrombosis. 79, 80 Some scholars have revealed that after providing calcium chelating agent EGTA, the biosynthesis of MVs was significantly reduced. 81 Deferiprone can inhibit iron-induced ROS production, reduce endothelial cell apoptosis and EMV release, and protect endothelial cells from iron-induced toxicity. 82 This reduces the content of various MVs in circulation and alleviates the damage of MVs to cells. In conclusion, drugs and reasonable diet can block the release of MVs and reduce the content of MVs in circulation, thereby alleviating the damage of MVs to cells.
In addition, most scholars have considered that the protective effect of stem cell MVs on mitigating receptor cell injury in vivo is probably due to the ability of MVs to carry parental microRNAs with regenerative function. 83 In recent years, some scholars have applied MVs secreted by stem cells to investigate tissue cell damage in clinical treatment, and this has become an effective method to alleviate the brain damage caused by cancer radiotherapy. 84 Stem cell MVs treatment is one of the effective ways to alleviate the progress of disease, and the therapeutic effect of stem cell MVs has been given more and more attention. Various physiological factors and different pathological stimuli may affect the production and composition of MVs, resulting in different active substances carried by MVs and different biological effects. Therefore, the mechanism of MVs and its active substances in the body is the key to identify disease markers. Previous studies have revealed the abnormal levels of MVs expressing CD62E and MIL-126-3P in pre-diabetic patients, 85 which may be a marker of endothelial dysfunction. On the other hand, mastering the biological process of MVs and its active substances that act on target cells is the key to preventing and treating diseases. This is a new hope for clinical treatment, which may be applied to the treatment of diseases in the future. 
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